APA (7th ed.) Citation

Bayarmagnai Weinstein, Bogdan Muresan, Sara Solano, Antonio Vaz de Macedo, YoonJung Lee, Yu-Chen Su, . . . David O. Carpenter. (2021). Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review. University of Minnesota Libraries Publishing.

Chicago Style (17th ed.) Citation

Bayarmagnai Weinstein, et al. Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells Versus Axicabtagene Ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review. University of Minnesota Libraries Publishing, 2021.

MLA (9th ed.) Citation

Bayarmagnai Weinstein, et al. Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells Versus Axicabtagene Ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review. University of Minnesota Libraries Publishing, 2021.